|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1997-10-20
|
|
pubmed:abstractText |
The prophylactic and therapeutic efficacy of interleukin-12 was studied by using murine models of herpes simplex virus infection. Prophylactic administration consisted of two intraperitoneal doses of interleukin-12 given 48 and 24 h prior to infection. Therapeutic intraperitoneal administration of interleukin-12 commenced 6 h after the mice were infected with herpes simplex virus and was continued daily for a total of 5 days. Interleukin-12 therapy improved the survival rates of mice with systemic herpes simplex virus infection compared with those of placebo-treated infected mice. Subcutaneous administration of interleukin-12 also improved the rate of survival of mice after systemic herpes simplex virus infection, although higher doses were required to give comparable effects. Combined prophylactic and therapeutic administration of interleukin-12 produced the greatest effect on survival after an otherwise lethal systemic infection. Intraperitoneal administration of interleukin-12 for 2 days before and 3 days after systemic infection with herpes simplex virus resulted in survival of 80% of the mice. These surviving mice were resistant to subsequent reinfection with herpes simplex virus. Such resistance was apparently specific for herpes simplex virus infection, since a second group of survivors succumbed to a lethal infection with murine cytomegalovirus. Infectious virus was recovered from lumbar ganglia explants dissected from survivors of prophylactic interleukin-12 therapy and cultured for 5 days in vitro, suggesting that interleukin-12 treatment did not prevent the establishment of latent herpes simplex virus infection. One action of interleukin-12 may be to enhance natural killer cell-mediated clearance of the virus. However, interleukin-12 therapy was also effective in mice carrying the beige mutation, which reduces natural killer cell lytic activity, suggesting that interleukin-12 has additional activities in vivo.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-1346797,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-1376951,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-166926,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-1673147,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-2504877,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-6227561,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-6249885,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-6310036,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-7494339,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-7499854,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-7624330,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-7658066,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-7807019,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-7853541,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-7869050,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-7905500,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-7908324,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-7911046,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-8031058,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-8102100,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-8102101,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-8163949,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-831755,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-8557990,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-8656012,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-8656046,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-8757640,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-8985195,
http://linkedlifedata.com/resource/pubmed/commentcorrection/9311865-9060687
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0022-538X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
71
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
7799-803
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:9311865-Acyclovir,
pubmed-meshheading:9311865-Animals,
pubmed-meshheading:9311865-Antiviral Agents,
pubmed-meshheading:9311865-Cercopithecus aethiops,
pubmed-meshheading:9311865-Drug Administration Schedule,
pubmed-meshheading:9311865-Female,
pubmed-meshheading:9311865-Herpesviridae Infections,
pubmed-meshheading:9311865-Interleukin-12,
pubmed-meshheading:9311865-Mice,
pubmed-meshheading:9311865-Mice, Inbred BALB C,
pubmed-meshheading:9311865-Mice, Inbred C57BL,
pubmed-meshheading:9311865-Time Factors,
pubmed-meshheading:9311865-Vero Cells
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Interleukin-12 exhibits potent antiviral activity in experimental herpesvirus infections.
|
|
pubmed:affiliation |
Virology Department, Roche Development Welwyn, Welwyn Garden City, Hertfordshire, United Kingdom.
|
|
pubmed:publicationType |
Journal Article
|
